{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T02:03:34Z","timestamp":1768269814211,"version":"3.49.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,10,29]],"date-time":"2020-10-29T00:00:00Z","timestamp":1603929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,10,29]],"date-time":"2020-10-29T00:00:00Z","timestamp":1603929600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Swiss National Science Foundation","doi-asserted-by":"crossref","award":["324730-165956"],"award-info":[{"award-number":["324730-165956"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001711","name":"Swiss National Science Foundation","doi-asserted-by":"crossref","award":["324730-166204"],"award-info":[{"award-number":["324730-166204"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"crossref"}]},{"name":"OPO Foundation"},{"name":"Isaac Dreyfus Foundation"},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006389","name":"University of Geneva","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006389","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1007\/s40262-020-00946-3","type":"journal-article","created":{"date-parts":[[2020,10,29]],"date-time":"2020-10-29T19:02:35Z","timestamp":1603998155000},"page":"379-390","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Pharmacokinetic\/Pharmacodynamic Modelling to Describe the Cholesterol Lowering Effect of Rosuvastatin in People Living with HIV"],"prefix":"10.1007","volume":"60","author":[{"name":"and the Swiss HIV Cohort Study","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9114-7793","authenticated-orcid":false,"given":"Perrine","family":"Courlet","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6419-9317","authenticated-orcid":false,"given":"Monia","family":"Guidi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susana","family":"Alves Saldanha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4223-6754","authenticated-orcid":false,"given":"Felix","family":"Stader","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Traytel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0933-7833","authenticated-orcid":false,"given":"Matthias","family":"Cavassini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0088-5078","authenticated-orcid":false,"given":"Marcel","family":"Stoeckle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0639-5536","authenticated-orcid":false,"given":"Thierry","family":"Buclin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2312-7050","authenticated-orcid":false,"given":"Catia","family":"Marzolini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9840-1325","authenticated-orcid":false,"given":"Laurent A.","family":"Decosterd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0660-082X","authenticated-orcid":false,"given":"Chantal","family":"Csajka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,10,29]]},"reference":[{"issue":"3","key":"946_CR1","doi-asserted-by":"publisher","first-page":"e2010034","DOI":"10.4084\/mjhid.2010.034","volume":"2","author":"DK de Gaetano","year":"2010","unstructured":"de Gaetano DK, Cauda R, Iacoviello L. HIV infection, antiretroviral therapy and cardiovascular risk. Mediterr J Hematol Infect Dis. 2010;2(3):e2010034.","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"1","key":"946_CR2","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1186\/s12879-018-3162-1","volume":"18","author":"OA Uthman","year":"2018","unstructured":"Uthman OA, Nduka C, Watson SI, Mills EJ, Kengne AP, Jaffar SS, et al. Statin use and all-cause mortality in people living with HIV: a systematic review and meta-analysis. BMC Infect Dis. 2018;18(1):258.","journal-title":"BMC Infect Dis"},{"issue":"3","key":"946_CR3","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1002\/lt.22225","volume":"17","author":"A Moreno","year":"2011","unstructured":"Moreno A, Fortun J, Graus J, Rodriguez-Gandia MA, Quereda C, Perez-Elias MJ, et al. Severe rhabdomyolysis due to rosuvastatin in a liver transplant subject with human immunodeficiency virus and immunosuppressive therapy-related dyslipidemia. Liver Transpl. 2011;17(3):331\u20133.","journal-title":"Liver Transpl"},{"issue":"3","key":"946_CR4","doi-asserted-by":"publisher","first-page":"435","DOI":"10.3851\/IMP1747","volume":"16","author":"CT de Kanter","year":"2011","unstructured":"de Kanter CT, Keuter M, van der Lee MJ, Koopmans PP, Burger DM. Rhabdomyolysis in an HIV-infected patient with impaired renal function concomitantly treated with rosuvastatin and lopinavir\/ritonavir. Antiviral Ther. 2011;16(3):435\u20137.","journal-title":"Antiviral Ther"},{"issue":"10","key":"946_CR5","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1124\/dmd.108.021410","volume":"36","author":"S Kitamura","year":"2008","unstructured":"Kitamura S, Maeda K, Wang Y, Sugiyama Y. Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. Drug Metab Dispos. 2008;36(10):2014\u201323.","journal-title":"Drug Metab Dispos"},{"key":"946_CR6","doi-asserted-by":"crossref","unstructured":"Patilea-Vrana G, Unadkat JD. Transport vs. metabolism: what determines the pharmacokinetics and pharmacodynamics of drugs? Insights from the extended clearance model. Clin Pharmacol Ther. 2016;100(5):413\u20138.","DOI":"10.1002\/cpt.437"},{"issue":"2","key":"946_CR7","doi-asserted-by":"publisher","first-page":"56","DOI":"10.5501\/wjv.v4.i2.56","volume":"4","author":"J da Cunha","year":"2015","unstructured":"da Cunha J, Maselli LM, Stern AC, Spada C, Bydlowski SP. Impact of antiretroviral therapy on lipid metabolism of human immunodeficiency virus-infected patients: old and new drugs. World J Virol. 2015;4(2):56\u201377.","journal-title":"World J Virol"},{"key":"946_CR8","unstructured":"Courlet P, Livio F, Alves Saldanha S, Scherrer A, Battegay M, Cavassini M, et al. Real-life management of drug-drug interactions between antiretrovirals and statins. J Antimicrob Chemother. 2020."},{"issue":"6","key":"946_CR9","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1177\/0091270011407494","volume":"52","author":"D Samineni","year":"2012","unstructured":"Samineni D, Desai PB, Sallans L, Fichtenbaum CJ. Steady-state pharmacokinetic interactions of darunavir\/ritonavir with lipid-lowering agent rosuvastatin. J Clin Pharmacol. 2012;52(6):922\u201331.","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"946_CR10","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1097\/QAD.0000000000002372","volume":"34","author":"P Courlet","year":"2020","unstructured":"Courlet P, Stader F, Guidi M, Alves Saldanha S, Stoeckle M, Cavassini M, et al. Pharmacokinetic profiles of boosted darunavir, dolutegravir and lamivudine in aging people living with HIV. AIDS. 2020;34(1):103\u20138.","journal-title":"AIDS"},{"key":"946_CR11","doi-asserted-by":"crossref","unstructured":"Courlet P, Livio F, Guidi M, Cavassini M, Battegay M, Stoeckle M, et al. Polypharmacy, drug-drug interactions, and inappropriate drugs: new challenges in the aging population with HIV. Open Forum Infect Dis. 2019;6(12):ofz531.","DOI":"10.1093\/ofid\/ofz531"},{"issue":"9","key":"946_CR12","doi-asserted-by":"publisher","first-page":"2575","DOI":"10.1185\/03007990802312807","volume":"24","author":"TB Tzeng","year":"2008","unstructured":"Tzeng TB, Schneck DW, Birmingham BK, Mitchell PD, Zhang H, Martin PD, et al. Population pharmacokinetics of rosuvastatin: implications of renal impairment, race, and dyslipidaemia. Curr Med Res Opin. 2008;24(9):2575\u201385.","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"946_CR13","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000180580","volume":"16","author":"DW Cockcroft","year":"1976","unstructured":"Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31\u201341.","journal-title":"Nephron"},{"issue":"2","key":"946_CR14","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/acel.12547","volume":"16","author":"R van den Berg","year":"2017","unstructured":"van den Berg R, Noordam R, Kooijman S, Jansen SWM, Akintola AA, Slagboom PE, et al. Familial longevity is characterized by high circadian rhythmicity of serum cholesterol in healthy elderly individuals. Aging Cell. 2017;16(2):237\u201343.","journal-title":"Aging Cell"},{"key":"946_CR15","doi-asserted-by":"publisher","first-page":"121733","DOI":"10.1016\/j.jchromb.2019.121733","volume":"1125","author":"P Courlet","year":"2019","unstructured":"Courlet P, Spaggiari D, Desfontaine V, Cavassini M, Alves Saldanha S, Buclin T, et al. UHPLC-MS\/MS assay for simultaneous determination of amlodipine, metoprolol, pravastatin, rosuvastatin, atorvastatin with its active metabolites in human plasma, for population-scale drug-drug interactions studies in people living with HIV. J Chromatogr B Analyt Technol Biomed Life Sci. 2019;1125:121733.","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"946_CR16","doi-asserted-by":"crossref","unstructured":"Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2019;.","DOI":"10.15829\/1560-4071-2020-3826"},{"issue":"1","key":"946_CR17","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.cmpb.2010.04.018","volume":"101","author":"RJ Keizer","year":"2011","unstructured":"Keizer RJ, van Benten M, Beijnen JH, Schellens JH, Huitema AD. Pirana and PCluster: a modeling environment and cluster infrastructure for NONMEM. Comput Methods Programs Biomed. 2011;101(1):72\u20139.","journal-title":"Comput Methods Programs Biomed"},{"issue":"3","key":"946_CR18","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.cmpb.2005.04.005","volume":"79","author":"L Lindbom","year":"2005","unstructured":"Lindbom L, Pihlgren P, Jonsson EN. PsN-Toolkit: a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed. 2005;79(3):241\u201357.","journal-title":"Comput Methods Programs Biomed"},{"issue":"6","key":"946_CR19","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1097\/FJC.0b013e31817b5b5a","volume":"51","author":"AJ Busti","year":"2008","unstructured":"Busti AJ, Bain AM, Hall RG 2nd, Bedimo RG, Leff RD, Meek C, et al. Effects of atazanavir\/ritonavir or fosamprenavir\/ritonavir on the pharmacokinetics of rosuvastatin. J Cardiovasc Pharmacol. 2008;51(6):605\u201310.","journal-title":"J Cardiovasc Pharmacol"},{"key":"946_CR20","unstructured":"Custodio JM, West S, SenGupta D, Zari A, Humeniuk R, Ling KH, et al. Evaluation of the drug-drug interaction potential between cobicistat-boosted protease inhibitors and statins. [abstract O_04]. 18th International Workshop on Clinical Pharmacology of Antiviral Therapy; 14\u201316 June 2017; Chicago (IL)."},{"issue":"10","key":"946_CR21","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1002\/psp4.12015","volume":"4","author":"RV Overgaard","year":"2015","unstructured":"Overgaard RV, Ingwersen SH, Tornoe CW. Establishing good practices for exposure-response analysis of clinical endpoints in drug development. CPT Pharmacometrics Syst Pharmacol. 2015;4(10):565\u201375.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"4","key":"946_CR22","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1111\/j.1365-2125.2004.02170.x","volume":"58","author":"U Wahlby","year":"2004","unstructured":"Wahlby U, Thomson AH, Milligan PA, Karlsson MO. Models for time-varying covariates in population pharmacokinetic-pharmacodynamic analysis. Br J Clin Pharmacol. 2004;58(4):367\u201377.","journal-title":"Br J Clin Pharmacol"},{"key":"946_CR23","unstructured":"European AIDS Clinical Society. Guidelines version 10.0. 2019. Available from: https:\/\/www.eacsociety.org\/files\/2019_guidelines-10.0_final.pdf. [Accessed 1 Oct 2020]."},{"issue":"2","key":"946_CR24","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","volume":"13","author":"M Bergstrand","year":"2011","unstructured":"Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011;13(2):143\u201351.","journal-title":"AAPS J"},{"issue":"1","key":"946_CR25","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s00228-015-1946-4","volume":"72","author":"M Macpherson","year":"2016","unstructured":"Macpherson M, Hamren B, Braamskamp MJ, Kastelein JJ, Lundstrom T, Martin PD. Population pharmacokinetics of rosuvastatin in pediatric patients with heterozygous familial hypercholesterolemia. Eur J Clin Pharmacol. 2016;72(1):19\u201327.","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"946_CR26","doi-asserted-by":"publisher","first-page":"55","DOI":"10.12793\/tcp.2016.24.1.55","volume":"24","author":"W Park","year":"2016","unstructured":"Park W, Jang D, Han S, Yim D. Mixed-effects analysis of increased rosuvastatin absorption by coadministrered telmisartan. Transl Clin Pharmacol. 2016;24(1):55\u201362.","journal-title":"Transl Clin Pharmacol"},{"issue":"6","key":"946_CR27","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1248\/bpb.33.1082","volume":"33","author":"T Aoyama","year":"2010","unstructured":"Aoyama T, Omori T, Watabe S, Shioya A, Ueno T, Fukuda N, et al. Pharmacokinetic\/pharmacodynamic modeling and simulation of rosuvastatin using an extension of the indirect response model by incorporating a circadian rhythm. Biol Pharm Bull. 2010;33(6):1082\u20137.","journal-title":"Biol Pharm Bull"},{"issue":"6","key":"946_CR28","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1038\/sj.clpt.6100220","volume":"82","author":"MK Pasanen","year":"2007","unstructured":"Pasanen MK, Fredrikson H, Neuvonen PJ, Niemi M. Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther. 2007;82(6):726\u201333.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"946_CR29","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/clpt.2009.79","volume":"86","author":"JE Keskitalo","year":"2009","unstructured":"Keskitalo JE, Zolk O, Fromm MF, Kurkinen KJ, Neuvonen PJ, Niemi M. ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther. 2009;86(2):197\u2013203.","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"946_CR30","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1097\/QAI.0b013e318160a542","volume":"47","author":"JJ Kiser","year":"2008","unstructured":"Kiser JJ, Gerber JG, Predhomme JA, Wolfe P, Flynn DM, Hoody DW. Drug\/drug interaction between lopinavir\/ritonavir and rosuvastatin in healthy volunteers. J Acquir Immune Defic Syndr. 2008;47(5):570\u20138.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"3","key":"946_CR31","doi-asserted-by":"publisher","first-page":"163","DOI":"10.3109\/00498250903509375","volume":"40","author":"P Annaert","year":"2010","unstructured":"Annaert P, Ye ZW, Stieger B, Augustijns P. Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1. Xenobiotica. 2010;40(3):163\u201376.","journal-title":"Xenobiotica"},{"key":"946_CR32","unstructured":"Janssen-Cilag. Prezista summary of product characteristics. June 2012."},{"issue":"3","key":"946_CR33","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1111\/j.1472-8206.2006.00404.x","volume":"20","author":"DW Faltaos","year":"2006","unstructured":"Faltaos DW, Urien S, Carreau V, Chauvenet M, Hulot JS, Giral P, et al. Use of an indirect effect model to describe the LDL cholesterol-lowering effect by statins in hypercholesterolaemic patients. Fundam Clin Pharmacol. 2006;20(3):321\u201330.","journal-title":"Fundam Clin Pharmacol"},{"issue":"18","key":"946_CR34","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1097\/QAD.0000000000001675","volume":"31","author":"JM Gatell","year":"2017","unstructured":"Gatell JM, Assoumou L, Moyle G, Waters L, Johnson M, Domingo P, et al. Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk. AIDS. 2017;31(18):2503\u201314.","journal-title":"AIDS"},{"issue":"1","key":"946_CR35","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1186\/s12879-018-3268-5","volume":"18","author":"L Taramasso","year":"2018","unstructured":"Taramasso L, Tatarelli P, Ricci E, Madeddu G, Menzaghi B, Squillace N, et al. Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large observational cohort study (SCOLTA). BMC Infect Dis. 2018;18(1):357.","journal-title":"BMC Infect Dis"},{"issue":"1","key":"946_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1310\/hct1401-1","volume":"14","author":"JL Casado","year":"2013","unstructured":"Casado JL, de Los SI, Del Palacio M, Garcia-Fraile L, Perez-Elias MJ, Sanz J, et al. Lipid-lowering effect and efficacy after switching to etravirine in HIV-infected patients with intolerance to suppressive HAART. HIV Clin Trials. 2013;14(1):1\u20139.","journal-title":"HIV Clin Trials"},{"issue":"2","key":"946_CR37","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1310\/hct0802-77","volume":"8","author":"TR Glass","year":"2007","unstructured":"Glass TR, Weber R, Vernazza PL, Rickenbach M, Furrer H, Bernasconi E, et al. Ecological study of the predictors of successful management of dyslipidemia in HIV-infected patients on ART: the Swiss HIV Cohort Study. HIV Clin Trials. 2007;8(2):77\u201385.","journal-title":"HIV Clin Trials"},{"issue":"2","key":"946_CR38","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/j.1468-1293.2005.00273.x","volume":"6","author":"WM El-Sadr","year":"2005","unstructured":"El-Sadr WM, Mullin CM, Carr A, Gibert C, Rappoport C, Visnegarwala F, et al. Effects of HIV disease on lipid, glucose and insulin levels: results from a large antiretroviral-naive cohort. HIV Med. 2005;6(2):114\u201321.","journal-title":"HIV Med"},{"issue":"8","key":"946_CR39","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1097\/QAD.0000000000000243","volume":"28","author":"MT May","year":"2014","unstructured":"May MT, Gompels M, Delpech V, Porter K, Orkin C, Kegg S, et al. Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy. AIDS. 2014;28(8):1193\u2013202.","journal-title":"AIDS"},{"issue":"1","key":"946_CR40","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1097\/QAD.0b013e328331d2ab","volume":"24","author":"E Aslangul","year":"2010","unstructured":"Aslangul E, Assoumou L, Bittar R, Valantin MA, Kalmykova O, Peytavin G, et al. Rosuvastatin versus pravastatin in dyslipidemic HIV-1-infected patients receiving protease inhibitors: a randomized trial. AIDS. 2010;24(1):77\u201383.","journal-title":"AIDS"},{"issue":"6","key":"946_CR41","doi-asserted-by":"publisher","first-page":"572","DOI":"10.2174\/157016208786501481","volume":"6","author":"L Calza","year":"2008","unstructured":"Calza L, Manfredi R, Colangeli V, Pocaterra D, Pavoni M, Chiodo F. Rosuvastatin, pravastatin, and atorvastatin for the treatment of hypercholesterolaemia in HIV-infected patients receiving protease inhibitors. Curr HIV Res. 2008;6(6):572\u20138.","journal-title":"Curr HIV Res"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-020-00946-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40262-020-00946-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-020-00946-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T16:23:13Z","timestamp":1669393393000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40262-020-00946-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,29]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["946"],"URL":"https:\/\/doi.org\/10.1007\/s40262-020-00946-3","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,29]]},"assertion":[{"value":"23 September 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Perrine Courlet, Laurent A. Decosterd, Susana Alves Saldanha, Felix Stader, Anna Traytel, Matthias Cavassini, Thierry Buclin, Chantal Csajka and Monia Guidi have no conflict of interest to declare. Marcel Stoeckle got fee\u2019s for advisory boards from Gilead, MSD, ViiV, Janssen-Cilag, Sandoz and Mepha, as well as grants for conferences from Gilead and MSD, yet unrelated to the present study. Catia Marzolini received a research grant from Gilead and speaker honoraria for her institution from MSD.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Open access funding provided by University of Geneva. This work was supported by two Swiss national grants (grant number 324730\u2013165956 to Laurent A. Decosterd [Lausanne] and 324730\u2013166204 to Catia Marzolini [Basel]) as well as the OPO and the Isaac Dreyfus Foundations to Catia Marzolini (Basel). The Swiss HIV Cohort Study #815 has received the 2017 Swiss HIV Cohort Study Abbvie Award (given\u00a0to Laurent A. Decosterd and Catia Marzolini).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The study protocol was reviewed and approved by the Ethics Committee of Vaud and northwest\/central Switzerland (CER VD 2018-00369), and registered in clinicaltrials.gov (NCT03515772).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Participants included in the study with rich sampling gave written informed consent before entering the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"PC wrote the manuscript and analyzed the data. MG and CC supervised the data analysis. SAS recorded data in a database. AT extracted data from the SHCS database. MC and MS recruited participants. CM and LAD designed the study and obtained fundings. All authors contributed towards the critical revision and approval of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}